Clinical Trials ·
The TRANSCEND-T2D-1 study investigates the efficacy and safety of retatrutide compared to placebo in adults with Type 2 Diabetes. This clinical trial is designed to assess how well retatrutide can manage glycemic control in participants who have not achieved adequate results with diet and exercise alone.
What this source covers
The TRANSCEND-T2D-1 study, registered under ClinicalTrials.gov (NCT06354660), aims to evaluate the effects of retatrutide on adults with Type 2 Diabetes experiencing inadequate glycemic control. The study is expected to last approximately 11 months and will involve up to 11 visits by participants. The primary focus is on understanding both the efficacy and safety profile of retatrutide in this patient population.
Why it matters for Retatrutide research
This study is significant as it contributes to the understanding of retatrutide's role in managing Type 2 Diabetes, particularly for those who have not responded adequately to lifestyle modifications alone. As diabetes continues to be a major global health issue, effective pharmacological interventions are essential. The findings from this trial could potentially inform treatment guidelines and clinical practices surrounding diabetes management.
Key findings or claims
- The study compares retatrutide with a placebo in adults with Type 2 Diabetes.
- It focuses on participants who have inadequate glycemic control with diet and exercise alone.
- The trial is designed to last about 11 months and may include up to 11 visits.
- The primary outcomes will assess both efficacy and safety of retatrutide.
- The source does not specify any numeric data or specific outcomes at this time.
Context and prior work
Retatrutide belongs to a class of medications that target multiple pathways involved in glucose metabolism, including GLP-1, GIP, and glucagon receptors. Prior research has indicated that agents acting on these pathways can lead to improved glycemic control and weight management in individuals with Type 2 Diabetes. The findings from the TRANSCEND-T2D-1 study will add to the existing literature by providing insights into the specific benefits and risks associated with retatrutide, which is critical for understanding its potential role in diabetes treatment.
Practical takeaways for researchers
Researchers should monitor the outcomes of the TRANSCEND-T2D-1 study closely, as it may provide valuable data on the effectiveness of retatrutide in a real-world clinical setting. The study's design, focusing on patients with inadequate control through lifestyle changes, highlights the need for effective pharmacological options. Additionally, understanding the safety profile of retatrutide will be crucial for its adoption in clinical practice.
FAQ
What is retatrutide?
Retatrutide is a novel medication being studied for its potential to improve glycemic control in individuals with Type 2 Diabetes.
How long will the TRANSCEND-T2D-1 study last?
The study is expected to last about 11 months and will involve multiple participant visits.
What are the primary outcomes of the study?
The primary outcomes include the efficacy and safety of retatrutide compared to placebo in the target population.
Source: ClinicalTrials.gov · NCT06354660 · published 2026-03-05.